Morgan Stanley
SGMT icon

Morgan Stanley’s Sagimet Biosciences SGMT Stock Holding History

Morgan Stanley’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$790K Buy
102,227
+8,920
+10% +$60.7K ﹤0.01% 5334
2026
Q1 		$488K Buy
93,307
+4,063
+5% +$22.6K ﹤0.01% 5498
2025
Q4 		$528K Sell
89,244
-156,833
-64% -$1.13M ﹤0.01% 5485
2025
Q3 		$1.69M Buy
246,077
+50,583
+26% +$410K ﹤0.01% 4884
2025
Q2 		$1.49M Sell
195,494
-80,558
-29% -$340K ﹤0.01% 4890
2025
Q1 		$900K Sell
276,052
-2,143
-0.8% -$8.99K ﹤0.01% 5051
2024
Q4 		$1.25M Buy
278,195
+6,763
+2% +$34.3K ﹤0.01% 4974
2024
Q3 		$752K Sell
271,432
-67,761
-20% -$209K ﹤0.01% 5204
2024
Q2 		$1.16M Buy
339,193
+257,974
+318% +$1.18M ﹤0.01% 4870
2024
Q1 		$440K Buy
81,219
+69,305
+582% +$498K ﹤0.01% 5372
2023
Q4 		$64.6K Sell
11,914
-5,550
-32% -$26.2K ﹤0.01% 6079
2023
Q3 		$154K Buy
+17,464
New +$233K ﹤0.01% 5698

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Morgan Stanley's SGMT Position: Q2 2026 in Review

Morgan Stanley increased its Sagimet Biosciences (SGMT) stake by 9.6% in Q2 2026, buying an estimated $60.7K and bringing the position to 102,227 shares worth $790K. The position accounts for ﹤0.01% of the portfolio, ranked #5334.

Morgan Stanley first reported a position in SGMT in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.69M in Q3 2025. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Morgan Stanley held 102,227 shares of Sagimet Biosciences worth $790K as of Q2 2026.
  • Morgan Stanley bought 8,920 Sagimet Biosciences shares in Q2 2026, an estimated $60.7K.
  • Sagimet Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5334 holding.
  • Morgan Stanley first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 12 quarters since.
  • Morgan Stanley's Sagimet Biosciences position peaked at $1.69M in Q3 2025.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.